Sign in
WithdrawnPhase 4

Natesto Testosterone Nasal Gel for Hypogonadal Men

Key facts

Who runs it
University of Utah
Where
Salt Lake City, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 4
Started
1 Jan 2023
Ended
1 Apr 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Natesto Nasal Product
  • Placebo
Record updated
21 December 2022
Why it stopped
They study lost funding and decided to close the study down.

Who can take part

Age
18 years to 64 years
Sex
Men only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 34 criteriaShow less

Who can take part

  • Ability to understand and provide written informed consent for the study
  • Ability to read and complete electronic questionnaires in English
  • Adult males between the ages of 18-64 years
  • Mild-moderate ED based on SHIM score between 8-21 at study entry
  • Ability to take daily Tadalafil
  • Ability to undergo venipuncture
  • Ability to provide ejaculated semen sample
  • Stable female sexual partner with sexual activity at least 1-3 times/month
  • Hypogonadism defined as two (one done as SOC within the last 6 months and one done at the time of screening) early morning total testosterone lab values <300

Who cannot take part

  • Concurrent or Prior use of other exogenous testosterone or hormone therapy (SERM, aromatase inhibitor, gonadotropins) within the last 3 months
  • Concurrent use of other prescription medications for ED including PDE5 inhibitors, intracavernosal injection therapy, urethral suppositories
  • Concurrent use of nitrates in any form
  • Receipt of any investigational product within 4 weeks of study enrollment
  • History of pelvic radiation
  • Any progressive neurologic disease (Alzheimer's, Parkinson's, multiple sclerosis, etc)
  • History of penile prosthesis
  • History of prostatectomy
  • History of transurethral resection of prostate
  • History of stroke or myocardial infarction within the past 6 months
  • History of congestive heart failure
  • History of untreated obstructive sleep apnea
  • History of, current or suspected, prostate (abnormal DRE or elevated PSA >4.0) or breast cancer
  • History of azoospermia or oligospermia (<15 million/ml)
  • History of vasectomy
  • History of Priapism
  • History of Polycythemia Vera
  • Recurrent upper respiratory or sinus infection (>3 times/month for >6 months)
  • History of Diabetes (HBA1c >6.0)
  • History of liver disease (Serum transaminases > 2.5 times upper limit of normal)
  • History of chronic kidney disease (GFR<60 or Serum Cr >2)
  • Morbid Obesity - BMI >35
  • Hematocrit < 35% or > 54% at study entry
  • Spinal cord injury
  • Recurrent epistaxis (>3 times/month for >6 months)

Where in United States

  • University of Utah, Division of UrologySalt Lake City, United States

About the trial

What the trial wants to find out

To determine if testosterone deficient men who are using daily Tadalafil (a phosphodiesterase-5 Inhibitor), will have a significant improvement in erectile function and satisfaction with erectile dysfunction treatment when using on-demand Testosterone Nasal Gel (TNG) prior to sexual activity compared to placebo.

The 2 groups in the trial

  • NatestoExisting treatment, for comparison

    Natesto™ is a testosterone nasal gel that is FDA approved to treat low testosterone. It delivers testosterone through the nasal passages and it is then absorbed into the blood stream. The nasal pump is placed at the opening of each nostril and then the participant would press down on the nasal pump to apply the gel. Each application takes about 10 seconds and the nasal pump applies a thin layer of gel that absorbs through the lining of the nose.

    Treatment: Natesto Nasal Product

  • PlaceboPlacebo, for comparison

    This study involves a placebo. The placebo will look like the Natesto™ nasal pump and will contain a nasal gel, but without any active ingredients.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Placebo-Controlled Cross-Over Pilot Trial of Natesto Testosterone Nasal Gel on Demand for Hypogonadal Men With Sexual Dysfunction Using Daily Phosphodiesterase-5 Inhibitor
Record updated
21 December 2022